RT Journal Article
T1 Non-coding RNAs as mediators of epithelial to mesenchymal transition in metastatic colorectal cancers
A1 Nadukkandy, Aisha Shigna
A1 Blaize, Britny
A1 Kumar, Chethana D.
A1 Mori, Giulia
A1 Cordani, Marco
A1 Dinesh Kumar, Lekha
AB Colorectal cancer (CRC) remains a leading cause of cancer-related mortality globally, necessitating the development of innovative treatment strategies. Recent research has underscored the significant role of non-coding RNAs (ncRNAs) in CRC pathogenesis, offering new avenues for diagnosis and therapy. In this review, we delve into the intricate roles of various ncRNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), in CRC progression, epithelial-mesenchymal transition (EMT), metastasis, and drug resistance. We highlight the interaction of these ncRNAs with and regulation of key signaling pathways, such as Wnt/β-catenin, Notch, JAK-STAT, EGFR, and TGF-β, and the functional relevance of these interactions in CRC progression. Additionally, the review highlights the emerging applications of nanotechnology in enhancing the delivery and efficacy of ncRNA-based therapeutics, which could address existing challenges related to specificity and side effects. Future research directions, including advanced diagnostic tools, targeted therapeutics, strategies to overcome drug resistance, and the integration of personalized medicine approaches are discussed. Integrating nanotechnology with a deeper understanding of CRC biology offers the potential for more effective, targeted, and personalized strategies, though further research is essential to validate these approaches.
PB Elsevier
SN 0898-6568
YR 2025
FD 2025-01
LK https://hdl.handle.net/20.500.14352/118465
UL https://hdl.handle.net/20.500.14352/118465
LA eng
NO Nadukkandy AS, Blaize B, Kumar CD, Mori G, Cordani M, Kumar LD. Non-coding RNAs as mediators of epithelial to mesenchymal transition in metastatic colorectal cancers. Cellular Signalling 2025;127:111605. https://doi.org/10.1016/j.cellsig.2025.111605.
NO Funding:LDK, ASN, BB, is supported by CSIR-CCMB funds, CDK by CMC funds and M.C. is supported by grant RYC2021-031003I funded by MICIU/AEI/10.13039/501100011033 and, by European Union Next GenerationEU/PRTR.
NO European Commission
NO Ministerio de Ciencia, Innovación y Universidades (España)
DS Docta Complutense
RD 12 abr 2025